Please wait while the formulary information is being retrieved.
MOTOFEN (DIFENOXIN HCL/ATROPINE SULFATE)
- Diarrhea
1 mg-0.025 mg tablet
- 2 tablets (2 mg) by oral route to start, then 1 tablet (1 mg) after each loose stool not to exceed 8 tablets in 24 hours
Diarrhea
- 2 tablets (2 mg) by oral route to start, then 1 tablet (1 mg) every 3-4 hours as needed not to exceed 8 tablets in 24 hours
- 2 tablets (2 mg) by oral route to start, then 1 tablet (1 mg) after each loose stool not to exceed 8 tablets in 24 hours
- Depade
- naltrexone
- naltrexone microspheres
- pramlintide
- Revia
- Symlinpen 120
- Symlinpen 60
- Vivitrol
Contraindicated
- Azilect
- Eldepryl
- isocarboxazid
- K-tab
- Klor-con
- Klor-con 10
- Klor-con M10
- Klor-con M15
- Klor-con M20
- linezolid
- Marplan
- Matulane
- Medi-lyte
- methylene blue (antidote)
- Nardil
- Parnate
- phenelzine
- potassium chloride
- potassium citrate
- potassium Cl-calcium phos-mag
- procarbazine
- rasagiline
- selegiline HCl
- sodium Cl-potassium chloride
- Thermotabs
- tranylcypromine
- Urocit-k 10
- Urocit-k 15
- Urocit-k 5
- Zelapar
- Zyvox
Severe
Moderate
- Adasuve
- Buprenex
- buprenorphine
- buprenorphine-naloxone
- butorphanol tartrate
- Butrans
- chlorpromazine
- Compazine
- Compro
- Fanatrex
- fluphenazine decanoate
- fluphenazine HCl
- gabapentin
- gabapentin enacarbil
- Gralise
- Gralise 30-day Starter Pack
- Haldol
- Haldol Decanoate
- haloperidol
- haloperidol decanoate
- haloperidol lactate
- Horizant
- loxapine
- loxapine succinate
- Loxitane
- nalbuphine
- Neurontin
- perphenazine
- perphenazine-amitriptyline
- Phenadoz
- Phenergan
- prochlorperazine
- prochlorperazine Edisylate
- prochlorperazine maleate
- promethazine
- Promethazine Vc
- Promethazine Vc-codeine
- promethazine-codeine
- promethazine-DM
- promethazine-phenyleph-codeine
- promethazine-phenylephrine
- Promethegan
- Suboxone
- thioridazine
- trifluoperazine
- Zubsolv
- Achalasia of esophagus
- Angle-closure glaucoma
- Atony of colon
- Clostridium difficile infection
- Hemorrhagic shock
- Myasthenia gravis
- Paralytic ileus
- Pyloroduodenal obstruction
- Severe ulcerative colitis
- Toxic megacolon
- Toxin-mediated diarrhea
Contraindicated
- Abnormal hepatic function tests
- Autonomic dysreflexia
- Benign prostatic hyperplasia
- Bladder outflow obstruction
- Dehydration
- Disease of liver
- Gastric ulcer
- Gastrointestinal obstruction
- Hiatal hernia
- Reflux esophagitis
- Tachyarrhythmia
- Toxin-mediated diarrhea
- Ulcerative colitis
- Urinary retention
- Urinary tract obstructive uropathy
Severe
Moderate
- Alcoholism
- Chronic heart failure
- Chronic pulmonary disease
- Coronary artery disease
- Disease of liver
- Down's syndrome
- Drowsy
- Drug abuse
- Hypertension
- Hyperthyroidism
- Kidney disease with reduction in GFR
- Salivary secretion disorder
MOTOFEN (DIFENOXIN HCL/ATROPINE SULFATE)
- Diarrhea
- None
- None
More Frequent
Severe
Less Severe
- None
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Paralytic ileus
- Toxic megacolon
Less Severe
- Acute confusion
- Blurred vision
- Dizziness
- Drowsy
- Dry skin
- Dysuria
- Fatigue
- Fever
- General weakness
- Headache disorder
- Insomnia
- Xerostomia
Contraindicated
Difenoxin
Contraindicated in children under 2 years of age.
- 1 Day – 2 Years
- 1 Contraindicated in children under 2 years of age.
Severe Precaution
None
Management or Monitoring Precaution
Atropine
Infants and children are more sensitive to anticholinergic and adverse effects. Adverse CNS effects onset may be sooner and with lower dose.
Safety and efficacy below the age of 12 have not been established.
- 1 Day – 13 Years
- Infants and children are more sensitive to anticholinergic and adverse effects. Adverse CNS effects onset may be sooner and with lower dose.
- 2 Years – 12 Years
- Infants and children are more sensitive to anticholinergic and adverse effects. Adverse CNS effects onset may be sooner and with lower dose.
Difenoxin
Infants and children are more sensitive to anticholinergic and adverse effects. Adverse CNS effects onset may be sooner and with lower dose.
Safety and efficacy below the age of 12 have not been established.
- 1 Day – 13 Years
- Safety and efficacy below the age of 12 have not been established.
- 2 Years – 12 Years
- Safety and efficacy below the age of 12 have not been established.
Atropine Sulfate (systemic)
- Severity Level:
2
- Additional Notes: Iv use may produce tachycardia in fetus
Difenoxin
- Severity Level:
C
- Additional Notes: Category c in combination product with atropine
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Atropine
None
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | None |
Difenoxin
None
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Atropine
Neuro/Psych-Anticholinergic effects may cause sedation, worsen cognitive impairment and increase fall risk. Cardiovascular-May cause orthostatic hypotension at higher doses. Gastrointestinal-May cause or worsen pre-existing constipation. Genitourinary-Best avoided in patients with urinary retention from any cause.
General-May be more susceptible to respiratory depression.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | Y | Y | N | N |
BEERS: Y HEDIS: Y STOPP: Y
Difenoxin
Neuro/Psych-Anticholinergic effects may cause sedation, worsen cognitive impairment and increase fall risk. Cardiovascular-May cause orthostatic hypotension at higher doses. Gastrointestinal-May cause or worsen pre-existing constipation. Genitourinary-Best avoided in patients with urinary retention from any cause.
General-May be more susceptible to respiratory depression.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | N | N | Y | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Diarrhea | |
| K59.1 | Functional diarrhea |
| P78.3 | Noninfective neonatal diarrhea |
| R19.7 | Diarrhea, unspecified |
| 0-9 | A-Z |
|---|---|
| K59.1 | Functional diarrhea |
| P78.3 | Noninfective neonatal diarrhea |
| R19.7 | Diarrhea, unspecified |
Formulary Reference Tool